Santini D, Galluzzo S, Vincenzi B, Schiavon G, Fratto E, Pantano F, Tonini G
Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy.
Ann Oncol. 2007 Jun;18 Suppl 6:vi164-7. doi: 10.1093/annonc/mdm249.
Bisphosphonate (BP) therapy has become a standard of therapy for patients with malignant bone disease. In vivo preclinical and preliminary clinical data indicate that BPs may prevent cancer treatment-induced bone loss and the onset of malignant bone disease in patients with early-stage cancer.
This review will describe the preclinical evidences of action of BPs on osteoclasts and tumor cells. In addition, the effects of principal BPs on skeletal disease progression in patients with breast cancer, prostate cancer, non-small-cell lung cancer and other cancers will be reported. The preliminary clinical data from retrospective trials on the effect of zoledronic acid (ZA) on survival will be described and the ongoing adjuvant phase III trial will be analyzed.
This review will describe the preliminary clinical evidences from prospective studies on the effect of ZA treatment on the prevention of bone metastasis.
双膦酸盐（BP）疗法已成为恶性骨病患者的标准治疗方法。体内临床前和初步临床数据表明，双膦酸盐可能预防癌症治疗引起的骨质流失以及早期癌症患者恶性骨病的发生。
本综述将描述双膦酸盐对破骨细胞和肿瘤细胞作用的临床前证据。此外，还将报告主要双膦酸盐对乳腺癌、前列腺癌、非小细胞肺癌和其他癌症患者骨骼疾病进展的影响。将描述关于唑来膦酸（ZA）对生存影响的回顾性试验的初步临床数据，并分析正在进行的辅助性III期试验。
本综述将描述关于ZA治疗对预防骨转移影响的前瞻性研究的初步临床证据。
